The purpose of this study is to assess the safety and tolerability of E5555 in Japanese subjects with coronary artery disease.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
240
E5555 50 mg (tablet) taken orally, once a day.
E5555 100 mg (tablet) taken orally, once a day.
E5555 200 mg (tablet) taken orally, once a day.
Unnamed facility
Ichinomiya, Aichi-ken, Japan
Unnamed facility
Gifu, Gifu, Japan
Unnamed facility
Safety and tolerability: Adverse events, bleeding events, clinical laboratory tests, Coagulation tests, vital signs and 12-lead ECG
Time frame: 6 months
Major cardiac adverse events, biomarkers, platelet aggregation inhibition, plasma concentration.
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Placebo (tablet) taken orally, once a day.
Ōgaki, Gifu, Japan
Unnamed facility
Asahikawa, Hokkaido, Japan
Unnamed facility
Chitose, Hokkaido, Japan
Unnamed facility
Sapporo, Hokkaido, Japan
Unnamed facility
Tomakomai, Hokkaido, Japan
Unnamed facility
Himeji, Hyōgo, Japan
Unnamed facility
Nishinomiya, Hyōgo, Japan
Unnamed facility
Tsuchiura, Ibaraki, Japan
...and 15 more locations